

AIIMS Jammu opens Centre for Advanced Genomics & Precision Medicine

28 April 2025 | News

The centre will accept samples from patients and healthcare providers across the country



The All India Institute of Medical Sciences (AIIMS) Jammu has officially initiated laboratory operations with the illumina NextSeq 2000 sequencing machine, at its newly established Centre for Advanced Genomics & Precision Medicine, marking a transformative step toward making affordable, precision-driven cancer care accessible to patients across India.

Inaugurating the state-of-the-art facility were key dignitaries, including Prof. (Dr) Shakti Kumar Gupta, Executive Director and CEO of AIIMS Jammu; Lt Gen Dr Sunil Kant, Dean Research and Medical Superintendent; Prof. Dr Meeta Gupta, Dean (Academics); Prof. Dr Shabab L Angurana, Associate Dean (Research); Shailender Slathia, Registrar; Dr Poonam Sharma, Head, Department of Pathology; and Dr Sudharshan, Vice President – Global Operations at 4baseCare.

The Centre, developed in collaboration with Bengaluru-based startup 4baseCare, is equipped with advanced Next Generation Sequencing (NGS) technology, offering comprehensive genomic profiling for cancer patients. This powerful capability enables clinicians to design highly personalised, targeted treatment plans tailored to each patient's unique molecular profile.

“By integrating cutting-edge genomic data with AI-powered diagnostics, the Centre is poised to significantly improve early disease detection, refine therapy choices, and minimize ineffective treatments — ultimately enhancing both patient outcomes and quality of life,” said Dr Sudharshan Elangovan , Vice President – Global Operations at 4baseCare.

Traditionally, access to such advanced genomic testing has been prohibitively expensive for many patients. However, with this initiative, high-quality NGS-based tests will now be made available at affordable costs, paving the way for greater inclusivity in precision oncology across India.

Further solidifying its role as a national referral hub, the Centre will accept samples from patients and healthcare providers across the country, ensuring that cutting-edge molecular diagnostics are accessible, regardless of geographical barriers.